New insights into the heart-kidney connection in ATTR-CM. Dr. Jeffrey Testani and Dr. C. Michael Gibson discuss new analyses showing that acoramidis was associated with early and sustained kidney-protective effects in patients with ATTR-CM—findings that may help explain the therapy’s early cardiovascular benefits and offer new perspectives on cardiorenal health.